HCPCS Level II Current in October 2026

S2150

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition

Release: October 2026
Effective: October 1, 2026

Official source

Official Coding Notes

Reproduced verbatim from the October 2026 HCPCS Level II files.

Note

"S" CODES ARE UNIQUE TEMPORARY CODES ESTABLISHED BY BCBSA AND HIAA FOR PRIVATE PAYOR USE. THEY ARE NOT VALID NOR PAYABLE BY MEDICARE.

Version History

How S2150 appears in each release imported from the official files, newest first.

October 2026 Effective October 1, 2026
Current

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition
July 2026 Effective July 1, 2026
Unchanged

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition
April 2026 Effective April 1, 2026
Unchanged

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition
January 2026 Effective January 1, 2026
Unchanged

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre-and post-transplant care in the global definition

Data Source

Code information on this page is derived from the October 2026 HCPCS Level II files published by CMS.

Release: October 2026
Effective: October 1, 2026
Source file: october-2026-alpha-numeric-hcpcs-file.zip

Official HCPCS Level II source files (opens in a new tab)

MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.

Look up another code

Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.